Identification of hemostatic genes expressed in human and rat leg muscles and a novel gene (LPP1/PAP2A) suppressed during prolonged physical inactivity (sitting)

Lipids in Health and Disease

Marc T Hamilton¹  Theodore W Zderic¹ 

[1] Inactivity Physiology Department, Pennington Biomedical Research Center, LA, Baton Rouge, 70808, USA

关键词: Sedentary;    Hindlimb unloading;    Physical activity;    Lysophosphatidic acid;    Lysophospholipid;   

Others  :  1160176
DOI  :  10.1186/1476-511X-11-137

 received in 2012-06-01, accepted in 2012-09-05,  发布年份 2012

【 摘 要 】

Background

Partly because of functional genomics, there has been a major paradigm shift from solely thinking of skeletal muscle as contractile machinery to an understanding that it can have roles in paracrine and endocrine functions. Physical inactivity is an established risk factor for some blood clotting disorders. The effects of inactivity during sitting are most alarming when a person develops the enigmatic condition in the legs called deep venous thrombosis (DVT) or “coach syndrome,” caused in part by muscular inactivity. The goal of this study was to determine if skeletal muscle expresses genes with roles in hemostasis and if their expression level was responsive to muscular inactivity such as occurs in prolonged sitting.

Methods

Microarray analyses were performed on skeletal muscle samples from rats and humans to identify genes associated with hemostatic function that were significantly expressed above background based on multiple probe sets with perfect and mismatch sequences. Furthermore, we determined if any of these genes were responsive to models of physical inactivity. Multiple criteria were used to determine differential expression including significant expression above background, fold change, and non-parametric statistical tests.

Results

These studies demonstrate skeletal muscle tissue expresses at least 17 genes involved in hemostasis. These include the fibrinolytic factors tetranectin, annexin A2, and tPA; the anti-coagulant factors TFPI, protein C receptor, PAF acetylhydrolase; coagulation factors, and genes necessary for the posttranslational modification of these coagulation factors such as vitamin K epoxide reductase. Of special interest, lipid phosphate phosphatase-1 (LPP1/PAP2A), a key gene for degrading prothrombotic and proinflammatory lysophospholipids, was suppressed locally in muscle tissue within hours after sitting in humans; this was also observed after acute and chronic physical inactivity conditions in rats, and exercise was relatively ineffective at counteracting this effect in both species.

Conclusions

These findings suggest that skeletal muscle may play an important role in hemostasis and that muscular inactivity may contribute to hemostatic disorders not only because of the slowing of blood flow per se, but also potentially because of the contribution from genes expressed locally in muscles, such as LPP1.

【 授权许可】

   
2012 Zderic and Hamilton; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Blair SN, Brodney S: Effects of physical inactivity and obesity on morbidity and mortality: current evidence and research issues. Med Sci Sports Exerc 1999, 31:S646-S662.
• [2]Morris JN, Heady JA, Raffle PAB: Coronary heart disease and physical inactivity of work. Lancet 1953, 1053:1111.
• [3]Hamilton MT, Hamilton DG, Zderic TW: Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes 2007, 56(11):2655-2667.
• [4]Homans J: Thrombosis of the deep leg veins due to prolonged sitting. N Engl J Med 1954, 250:148-149.
• [5]Naide M: Prolonged television viewing as a cause of venous and arterial thrombosis in legs. JAMA 1957, 165:681-682.
• [6]Simpson K: Shelter deaths from pulmonary embolism. Lancet 1940, 14:744.
• [7]El-Sayed MS, Ali N, El-Sayed Ali Z: Aggregation and activation of blood platelets in exercise and training. Sports Med 2005, 35(1):11-22.
• [8]Wang JS: Intense exercise increases shear-induced platelet aggregation in men through enhancement of von Willbrand factor binding, glycoprotein IIb/IIIa activation, and P-selectin expression on platelets. Eur J Appl Physiol 2004, 91:741-747.
• [9]Makris PE, Louizou C, Markakis C, Tsakiris DA, Mandalaki T: Long lasting sitting position and haemostasis. Thromb Haemost 1986, 55:119-121.
• [10]Schobersberger W, Mittermayr M, Innerhofer P, Sumann G, Schobersberger B, Klingler A, Simmer M, Streif W, Fischbach U, Fries D: Coagulation changes and edema formation during long-distance bus travel. Blood Coagul Fibrinolysis 2004, 15:419-425.
• [11]Lopez JA, Kearon C, Lee AY: Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2004, 2004:439-456.
• [12]Huber D, Cramer EM, Kaufmann JE, Meda P, Masse JM, Kruithof EK, Vischer UM: Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002, 99:3637-3645.
• [13]Hittel DS, Kraus WE, Hoffman EP: Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. J Physiol 2003, 548(Pt 2):401-410.
• [14]Bey L, Hamilton MT: Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low-intensity activity. J Physiol 2003, 551(Pt 2):673-682.
• [15]Fitts RH, Riley DR, Widrick JJ: Physiology of a microgravity environment invited review: microgravity and skeletal muscle. J Appl Physiol 2000, 89:823-839.
• [16]Bey L, Akunuri N, Zhao P, Hoffman EP, Hamilton DG, Hamilton MT: Patterns of global gene expression in rat skeletal muscle during unloading and low-intensity ambulatory activity. Physiol Genomics 2003, 13:157-167.
• [17]Liu WM, Mei R, Bartell DM, Di X, Webster TA, Ryder T: Rank-based algorithms for analysis of microarrays. Proc SPIE 2001, 4266:56-67.
• [18]Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001, 125:279-284.
• [19]Alderton F, Darroch P, Sambi B, McKie AH, Ahmed IS, Pyne N, Pyne S: G-protein-coupled receptor stimulation of the p42/p44 mitogen-activated protein kinase pathway is attenuated by lipid phosphate phosphatases 1, 1a, and 2 in human embryonic kidney 293 cells. J Biol Chem 2001, 276:13452-13460.
• [20]Haseruck N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, Siess W: The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 2004, 103:2585-2592.
• [21]Zhao Y, Usatyuk PV, Cummings R, Saatian B, He D, Watkins T, Morris A, Spannhake EW, Brindley DN, Natarajan V: Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. Biochem J 2005, 385(Pt 2):493-502.
• [22]Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, Tigyi G, Siess W: Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003, 108:741-747.
• [23]Sandmann G, Siess W, Essler M: Lysophosphatidic acid is the unique platelet-activating substance in human malignant ascites. Eur J Med Res 2003, 8:397-404.
• [24]Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G, Aepfelbacher M: Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A 1999, 96:6931-6936.
• [25]Smyth SS, Sciorra VA, Sigal YJ, Pamuklar Z, Wang Z, Xu Y, Prestwich GD, Morris AJ: Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity. J Biol Chem 2003, 278:43214-43223.
• [26]Cui MZ, Zhao G, Winokur AL, Laag E, Bydash JR, Penn MS, Chisolm GM, Xu X: Lysophosphatidic acid induction of tissue factor expression in aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2003, 23:224-230.
• [27]Olorundare OE, Peyruchaud O, Albrecht RM, Mosher DF: Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists. Blood 2001, 98:117-124.
• [28]Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT, Lee H, Tigyi G, Berliner JA: Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab Invest 1999, 79:1227-1235.
• [29]van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW: Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 2000, 20:E127-E133.
• [30]Yatomi Y, Ruan F, Hakomori S, Igarashi Y: Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood 1995, 86:193-202.
• [31]Takeya H, Gabazza EC, Aoki S, Ueno H, Suzuki K: Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood 2003, 102:1693-1700.
• [32]Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB: Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 2003, 9:3534-3545.
• [33]Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB: The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 2003, 63:1073-1082.
• [34]Jia YJ, Kai M, Wada I, Sakane F, Kanoh H: Differential localization of lipid phosphate phosphatases 1 and 3 to cell surface subdomains in polarized MDCK cells. FEBS Lett 2003, 552:240-246.